The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review.

Comorbidity Patient-reported outcomes Psoriatic arthritis Systematic literature review

Journal

Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 12 02 2020
pubmed: 10 4 2020
medline: 10 4 2020
entrez: 10 4 2020
Statut: ppublish

Résumé

A systematic literature review was conducted with the aim to analyse the impact of comorbidity on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA). A sensitive search strategy of the Medline, Embase and the Cochrane Library (up to March 2019) was applied to retrieve studies for inclusion in this systematic literature review. Abstracts of the ACR and EULAR scientific meetings were also searched. The selection criteria were: (1) patients with PsA (population) with a comorbidity (intervention) and (2) report of any impact of the comorbidity on PROs. Systematic literature reviews, randomized controlled trials and observational were included in this systematic literature review. Two of the authors selected the articles and collected the data. Eighteen articles were included in this systematic literature review, with most being cross-sectional studies that included more than 9000 patients with PsA. Some studies analysed the impact of an individual comorbidity, such as fibromyalgia (FM), and in others the analysis was according to the number of comorbidities. The most frequently analysed PROs were function, quality of life and fatigue. Analysis of the studies included in the review showed that patients with a higher number of comorbidities and/or more severe comorbidities reported worse impacts of their disease on function, patient's global assessment (PGA), pain, fatigue, work disability and quality of life. Specifically, FM had a negative impact on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), function, quality of sleep and quality of life; anxiety and depression had a negative impact on function and fatigue; metabolic syndrome had a negative impact on BASDAI, function, PGA and quality of life; obesity had a negative impact on function and pain; smoking (current and ex-smokers) had a negative impact on pain, function, fatigue, quality of life and overall health; alcohol intake had a negative impact on pain, function, fatigue, quality of life and overall health. The prevalence and impact of medical comorbidity on PROs are very high in patients with PsA.

Identifiants

pubmed: 32270447
doi: 10.1007/s40744-020-00202-x
pii: 10.1007/s40744-020-00202-x
pmc: PMC7211228
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

237-257

Références

Rheum Dis Clin North Am. 2015 Nov;41(4):677-98
pubmed: 26476226
J Rheumatol. 2013 Aug;40(8):1349-56
pubmed: 23772076
Best Pract Res Clin Rheumatol. 2018 Jun;32(3):390-400
pubmed: 31171310
Clin Rheumatol. 2018 Mar;37(3):661-666
pubmed: 29380165
Rheumatol Int. 2019 Jan;39(1):121-130
pubmed: 30426237
Clin Exp Rheumatol. 2019 May-Jun;37(3):512
pubmed: 30620284
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1593-601
pubmed: 22556134
J Rheumatol. 2014 Nov;41(11):2315-22
pubmed: 25362717
Clin Exp Rheumatol. 2013 Mar-Apr;31(2):318-9
pubmed: 23295140
Clin Cosmet Investig Dermatol. 2017 May 08;10:155-163
pubmed: 28507445
Ann Rheum Dis. 2014 Jun;73(6):1157-62
pubmed: 23771989
Rheumatology (Oxford). 2013 Sep;52(9):1708-14
pubmed: 23804223
Clin Rheumatol. 2017 Oct;36(10):2253-2260
pubmed: 28762060
Metab Syndr Relat Disord. 2014 Feb;12(1):43-8
pubmed: 24206172
Ann Rheum Dis. 2016 Jun;75(6):1016-23
pubmed: 26489703
J Rheumatol. 2018 Feb;45(2):213-217
pubmed: 29196385
Semin Arthritis Rheum. 2015 Jun;44(6):618-26
pubmed: 26058345
Rheumatol Int. 2018 Nov;38(11):2063-2068
pubmed: 30135972
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Int J Rheum Dis. 2021 Feb;24(2):183-188
pubmed: 32951342
Z Rheumatol. 2019 Dec;78(10):987-995
pubmed: 30421034
Clin Rheumatol. 2015 Mar;34(3):579-83
pubmed: 25024097
Arthritis Care Res (Hoboken). 2018 Apr;70(4):592-599
pubmed: 28772007
J Rheumatol. 2014 May;41(5):887-96
pubmed: 24692521
Rheumatology (Oxford). 2012 Mar;51(3):571-6
pubmed: 22157469
J Rheumatol. 2016 Sep;43(9):1749-54
pubmed: 27252430
J Rheumatol. 2011 May;38(5):898-903
pubmed: 21324965
Arthritis Res Ther. 2016 Dec 13;18(1):297
pubmed: 27964760
Medicine (Baltimore). 2019 Jan;98(4):e13955
pubmed: 30681555
Medicine (Baltimore). 2019 Jul;98(28):e16400
pubmed: 31305449
Arthritis Care Res (Hoboken). 2012 May;64(5):758-65
pubmed: 22231988
BMC Rheumatol. 2018 Sep 06;2:25
pubmed: 30886975
Health Qual Life Outcomes. 2009 Mar 18;7:25
pubmed: 19296831
Ann Rheum Dis. 2015 May;74(5):813-7
pubmed: 24431392
Ann Rheum Dis. 2013 Aug;72(8):1358-61
pubmed: 23291384
Rev Bras Reumatol. 2012 Dec;52(6):943-8
pubmed: 23223703
Clin Exp Rheumatol. 2014 May-Jun;32(3):342-8
pubmed: 24708934
J Am Acad Dermatol. 2015 Aug;73(2):327-9
pubmed: 26183981
J Autoimmun. 2010 May;34(3):J314-21
pubmed: 20034760
Clin Rheumatol. 2019 Jan;38(1):3-10
pubmed: 30338414
RMD Open. 2018 Jun 17;4(1):e000631
pubmed: 30018797

Auteurs

Juan D Cañete (JD)

Arthritis Unit, Rheumatology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.

Jose Antonio Pinto Tasende (JAP)

Rheumatology Department, Complexo Hospitalario Universitario de A Coruña-INIBIC, A Coruña, Spain.

Francisco José Rebollo Laserna (FJR)

Pfizer Medical Department, Alcobendas, Madrid, Spain.

Susana Gómez Castro (SG)

Pfizer Medical Department, Alcobendas, Madrid, Spain.

Rubén Queiro (R)

Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. rubenque7@yahoo.es.

Classifications MeSH